In Vitro Drug-Drug Interaction Studies
Identify Drug Interaction Risks Early
Drug-drug interactions (DDIs) can alter drug exposure, efficacy, or safety, making them one of the key risks evaluated during preclinical development. Identifying these risks early helps optimize candidate selection, informs DDI risk assessment, guides clinical study design, and helps meet regulatory expectations.
WuXi Biology and Testing provides in vitro drug-drug interaction studies ranging from fit-for-purpose early screens to regulatory-aligned assessment packages. Our integrated DMPK platform evaluates a candidate as both an object of an interaction and a potential precipitant, then places the findings in the context of its ADME, pharmacokinetic, and development profile.
In Vitro ADME Studies Annually
In Vivo Studies Annually
Successful IND Filings
Build a Stage-Appropriate DDI Strategy
A DDI program should evaluate two complementary questions: whether other drugs could alter the candidate's exposure and whether the candidate could alter the exposure of concomitant medications. The scope can evolve from early liability screening to a regulatory-aligned package as the compound advances.
Our in vitro DDI capabilities include:
- Metabolic pathway identification and reaction phenotyping
- Reversible and time-dependent enzyme inhibition
- Enzyme induction
- Transporter substrate and inhibition assessments
- Mechanistic follow-up studies
- Integrated interpretation, IVIVE, and support for PBPK modeling
This tiered approach helps focus resources on the most decision-relevant risks at each stage of development.
Evaluate Metabolism-Mediated DDI Risk
Metabolism-mediated studies determine which enzymes contribute to a candidate's clearance and whether the candidate or its relevant metabolites may inhibit or induce those enzymes. Human liver microsomes, hepatocytes, and recombinant enzyme systems can be selected according to the scientific question and stage of development.
Core assessments may include:
- Reversible inhibition of major CYP enzymes
- Time-dependent CYP inhibition
- CYP induction
- CYP and UGT reaction phenotyping
- UGT inhibition and additional enzyme studies when supported by the candidate's metabolic pathways
Frequently evaluated CYP enzymes include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5. Study design and follow-up should be driven by pathway contribution, observed potency, projected clinical exposure, and regulatory decision criteria.
Characterize Transporter-Mediated DDI Risk
Drug transporters can influence absorption, hepatic uptake, tissue distribution, and renal or biliary elimination. In vitro studies assess whether a candidate is a transporter substrate or inhibitor and help determine whether transporter-mediated interactions could alter exposure in patients.
Common regulatory transporters include:
- P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)
- Organic anion transporting polypeptides OATP1B1 and OATP1B3
- Organic anion transporters OAT1 and OAT3
- Organic cation transporter OCT2
- Multidrug and toxin extrusion transporters MATE1 and MATE2-K
Additional transporters, including OCT1, BSEP, and NTCP, can be investigated when relevant to the candidate's disposition, mechanism, or safety profile. Cell-based systems, membrane vesicles, and hepatocyte models can be integrated to address substrate, inhibition, and uptake-clearance questions.
Translate In Vitro Data into Development Decisions
DDI results are most informative when interpreted with metabolic stability, metabolite identification, plasma protein binding, permeability, and pharmacokinetic data. Integrated analysis helps distinguish a theoretical in vitro signal from a risk that may be relevant at projected clinical exposure
.
Our scientists can support:
- Candidate differentiation and risk-mitigation planning
- Static risk assessment and in vitro-in vivo extrapolation (IVIVE)
- PBPK model development and verification
- Planning for clinical DDI evaluations and concomitant-medication considerations
- Regulatory submission packages aligned with current regional and ICH guidance
This integrated strategy supports a more focused transition from discovery through IND-enabling development and clinical planning.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
You May Also Be Interested In
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
In vitro drug-drug interaction studies evaluate whether an investigational drug could be affected by metabolic enzymes or transporters, or could alter the disposition of a co-administered drug. These roles are often described as the object and precipitant of an interaction, respectively. Enzyme- and transporter-based assays provide the mechanistic data needed for risk assessment and follow-up planning.
Early DDI assessment identifies compounds that may inhibit or induce drug-metabolizing enzymes or transporters before significant development resources are invested. Detecting these liabilities early supports lead optimization, candidate selection, and safer clinical development. It also helps sponsors design appropriate follow-up studies and regulatory strategies.
In vitro DDI studies cannot directly predict clinical drug interactions, but they are essential for assessing risk. Experimental results from CYP inhibition, CYP induction, transporter studies, and reaction phenotyping are combined with pharmacokinetic data, PBPK modeling, and clinical considerations to determine whether additional in vivo or clinical DDI studies may be warranted.
CYP inhibition occurs when a drug decreases enzyme activity, potentially increasing exposure to co-administered drugs. CYP induction increases enzyme expression or activity, which can accelerate drug metabolism and reduce therapeutic exposure. Because these mechanisms have opposite clinical consequences, both are evaluated during DDI risk assessment.
Drug transporters regulate absorption, tissue distribution, and elimination. Inhibiting or altering transporter activity can significantly change systemic drug exposure even when metabolic pathways remain unchanged. Transporter studies complement CYP assays to provide a more complete understanding of DDI risk.
Many DDI studies begin during lead optimization or candidate selection and continue through IND-enabling development. Performing these studies early allows potential risks to be identified before clinical trials and provides valuable information for study design and regulatory planning.
Major regulatory agencies, including the FDA, EMA, PMDA, and NMPA, recommend evaluating the DDI potential of investigational drugs before clinical development. The specific studies required depend on the drug's properties, intended use, and observed in vitro findings. Early testing helps ensure that regulatory expectations are addressed efficiently.
While DDI assessments are traditionally associated with small molecules, they are also valuable for emerging therapeutic modalities when metabolism or transporter interactions are relevant. Depending on the mechanism of action and clearance pathways, studies may be applicable to peptides, targeted protein degraders, oligonucleotide conjugates, antibody-drug conjugates, and other novel modalities.
DDI data should be considered alongside metabolic stability, metabolite identification, protein binding, permeability, clearance pathways, and pharmacokinetic exposure. Integration helps determine whether an in vitro finding is likely to be relevant under anticipated clinical conditions. It also supports candidate decisions, PBPK modeling, and a focused clinical and regulatory strategy.